Fig. 7
PRMT6 Modulates Wnt-β-Catenin Pathway Activation via YTHDF2. A: GSEA in glioma samples from TCGA database, categorizing based on PRMT6 expression, indicates PRMT6 activation of Wnt-β-catenin pathway. B: Similar GSEA, based on YTHDF2 expression in TCGA database, suggests YTHDF2’s role in activating Wnt-β-catenin pathway. C-D: Analysis of Wnt-β-catenin pathway proteins in YTHDF2 or PRMT6 knockdown LN229 and U251 cells. F: YTHDF2 reintroduction in PRMT6 knockdown cells and its effect on Wnt-β-catenin pathway proteins. F: Illustration of m6A modification sites near the 3’ end of APC and GSK3β mRNA, potential YTHDF2 targets. G-H: MeRIP-qPCR analysis in LN229 cells to assess m6A modification levels near the 3’ end of APC and GSK3β mRNA, potentially recognized by YTHDF2, in the context of overexpression or normal expression of YTHDF2 and PRMT6, respectively. I: RIP-qPCR detection of YTHDF2 binding to APC and GSK3β mRNA in LN229 cells. J-K: mRNA stability assay measuring APC and GSK3β mRNA half-life in YTHDF2 or PRMT6 overexpressed cells